ISPOR 20TH ANNUAL INTERNATIONAL MEETING
May 16-20, 2015
Philadelphia Marriott Downtown
Philadelphia, PA, USA

PROGRAM

Early Registration Deadline: April 14, 2015

Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects

First Plenary Session: Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does It Matter?

Second Plenary Session: Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?

Third Plenary Session: Big Data, Big Systems, and Better Evidence: What Progress?

MEETING PROGRAM COMMITTEE

PROGRAM COMMITTEE CO-CHAIRS
Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Penny Mohr, MA, Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

RESEARCH REVIEW COMMITTEE CO-CHAIRS
Carl V. Asche, MBA, MSc, PhD, Research Professor of Medicine & Director, Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL, USA
James D. Chambers, PhD, MPHarm, MSc, Assistant Professor, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Jean Lachaine, PhD, Professor, University of Montreal and President, PeriPharm, Inc., Montreal, QC, Canada
Patrick W. Sullivan, PhD, Professor, Regis University School of Pharmacy, Denver, CO, USA

WORKSHOP REVIEW COMMITTEE CO-CHAIRS
Tanisha Carino, PhD, Executive Vice President, Avalere Health, Washington, DC, USA
Shelby D. Reed, PhD, RPh, Professor, Department of Medicine, Center for Clinical and Genetic Economics, Duke Clinical Research Institute and Member, Duke Cancer Institute, Durham, NC, USA

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS
Chris Leibman, MS, PharmD, Vice President, HEOR – Global Market Access, Biogen, Cambridge, MA, USA
Brian Rittenhouse, PhD, Associate Professor of Social and Administrative Sciences, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, USA

Meeting information available at: www.ispor.org

#ISPORPhila
SATURDAY, MAY 16

**ALL DAY COURSES 8:00AM-5:00PM**

**INTRODUCTION TO PHARMACOECONOMICS**
Lorne Basskin, PharmD, Brown University
Incorporate pharmacoconomics into study design and data analysis; collect and calculate costs of different alternatives; determine the economic impact of clinical outcomes; identify, track, and assign costs to health care resources.

**BAYESIAN ANALYSIS – OVERVIEW AND APPLICATIONS**
Christopher Hollenbeck, PhD, Penn State College of Medicine; David J. Vanness, PhD, University of Wisconsin
Review the Bayesian approach and its applications to HEOR.

**INTRODUCTION TO DATABASE ANALYSIS OF OBSERVATIONAL STUDIES**
James McGlynn, MD, MPP; Neil Hawkins, PhD
Discuss principles and practice of decision analysis; construct decision trees; understand mechanisms of tree evaluation; acquire skills in interpreting published decision analyses.

**ADVANCED PATIENT-REPORTED OUTCOMES**
Andreas Pfeilschifter, PhD and Charles Petrie, PhD, Pfizer Inc.
Learn methods for measuring quality of life, health status, and other types of health outcomes. Evaluate theoretical frameworks, reliability, validity, responsiveness, and administration methods, respondent/administrative burdens, and issues of analysis and interpretation.

**INTRODUCTION TO CONJOINT ANALYSIS**
A. Brett Hauber, PhD, RTI Health Solutions; Deborah Marshall, PhD, MHSIA, University of Calgary
Discuss the conceptual basis for quantifying decision-maker preferences for medical interventions. Review design and analytical issues to obtain valid empirical preference estimates.

**ELEMENTS OF PHARMACEUTICAL/BIOTECH MODELS**
Mark Roberts, MD, MPP; University of Pittsburgh
Analyze theory and practice of these arrangements using WinBUGS case studies.

**BUDGET IMPACT ANALYSIS: CONCEPTS – APPLICATIONS**
Praveen Thokala, PhD
Examine the conceptual models and gain an understanding of useful graphic tools for illustrating these concepts.

**APPLIED BAYESIAN MODELS**
Joseph Cappelleri, PhD, MPH, Pfizer Inc.; Jeroen Jansen, PhD
Learn how graph analytics are used to deal with issues of data quality and completeness, the implications for the conclusions drawn, and whether the challenges still lie.

**MARKETING STRATEGIES**
Sarah Tutt, PhD, University of York
Engage in experimental learning opportunities focusing on marketing strategies.

**DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES – CONCEPTS**
J. Jaime Caro, MDMC, FRCP, FACP and Jörgen Möller, MSc Mech Eng
Gain a basic understanding of the key concepts of discrete event simulation.

**STATISTICAL METHODS IN ECONOMIC EVALUATIONS**
Shelby Reed, PhD, RPh and Brad Hammill, MS, Duke Clinical Research Institute
Discuss effect of distributional assumptions, univariate and multivariable analysis data, sample size and power calculations, and sampling uncertainty.

**RISK-SHARING/PERFORMANCE-BASED ARRANGEMENTS FOR DRUGS AND OTHER MEDICAL PRODUCTS**
Adrian Tovey, MA, MPhil, Office of Health Economics; Lou Garrison, PhD and Josh Carlson, PhD, University of Washington
Analyze theory and practice of these arrangements using examples from Europe, US, and Australia.

**NEW! DEVELOPMENT OF CONCEPTUAL MODELS**
Neil Hawkins, PhD, CStat, London School of Hygiene and Tropical Medicine; Elisabeth Fenwick, PhD, MSc, ICON Plc.; Beth Woods, MSc and Mark Sculpher, PhD, MSc, University of York
Review important practical aspects of the development of conceptual models and gain an understanding of useful graphic tools for illustrating these concepts.

**APPLICATIONS IN USING LARGE DATABASES**
Diana Brixner, PhD, RPh and Joanne LaFleur, PharmD, MSPH, University of Utah; John Parkinson, PhD, CPhD; Michael Eddy, PhD, PharmD, Xcenda, LLC
Discuss various databases including how to access information and how researchers utilize the information.

**PATIENT-REPORTED OUTCOMES – ITEM RESPONSE THEORY**
Bryce Reeve, PhD, University of North Carolina at Chapel Hill
Review the basics of IRT models and their applications to improve health outcomes measurement.

**USE OF INSTRUMENTAL VARIABLES IN OBSERVATIONAL STUDIES**
Benjamin Craig, PhD, Moffit Cancer Center; Bradley Martin, PharmD, RPh, PhD, University of Arkansas for Medical Sciences; Antoine El Khoury, PhD, MS, Johnson & Johnson
Analyze sample selection models and their applications (two-stage least squares, intuition, RCTs). Engage in interactive exercises using STATA.

**INTRODUCTION TO BUDGET IMPACT ANALYSIS: A 6-STEP APPROACH**
C. Daniel Mullins, PhD, University of Maryland; Josephine Mauskopf, PhD and Stephanie Earnshaw, PhD, RTI Health Solutions
Learn methods to determine cost-of-illness of a health condition and how to estimate the impact of new health care technologies.

**NEW! INTRODUCTION TO BIG DATA ANALYSIS: GRAPH ANALYTICS**
David R. Holmes III, PhD, Mayo Clinic College of Medicine
Learn how graph analytics are used to deal with issues of data quality and completeness, the implications for the conclusions drawn, and whether the challenges still lie.

**BUDGET IMPACT ANALYSIS: APPLICATIONS & DESIGN ISSUES**
Stephanie Earnshaw, PhD, MS, Anita Brogan, PhD, and Sorrel Wolowocz, PhD, RTI Health Solutions
Engage in experimental learning opportunities focusing on key decision issues related to accuracy of budget impact estimation as well as applicability to decision makers.

**DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES – APPLICATIONS**
J. Jaime Caro, MDMC, FRCP, FACP and Jörgen Möller, MSc Mech Eng
This course explores practical, hands-on discrete event simulation exercises using specific software.

**NETWORK META-ANALYSIS**
Joseph Cappelleri, PhD, MPH, Pfizer Inc.; Jeroen Jansen, PhD, Redwood Outcomes
Understand fundamentals/concepts of network meta-analysis using WinBUGS case studies.

**USE OF PROPENSITY SCORES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS**
John Seeger, PharmD, DrPH, Harvard Medical School/B Brigham and Women’s Hospital; Jeremy Rassen, ScD, Aetion, Inc.
Learn bias and methods for causal inference in observational studies and how propensity scores can reduce bias. Understand risk adjustment models, confounding, p-values of standard adjustment, and propensity scoring methodology.

**ADVANCED DECISION MODELLING FOR HEALTH ECONOMIC EVALUATIONS**
Andrew Briggs, DPhil, MSc, University of Glasgow; Mark Sculpher, PhD, MSc, University of York
Discuss decision modeling, making models probabilistic to capture parameter uncertainty, how to analyze and present results, and how to interpret and apply results.

**NEW! USING MULTI-CRITERIA DECISION ANALYSIS IN HEALTH CARE DECISION MAKING: APPROACHES & APPLICATIONS**
Maarten I. Jizerman, PhD, University of Twente; Kevin Marsh, PhD, Evidera; Nancy Devlin, PhD, Office of Health Economics; Praveen Thokala, PhD, University of Sheffield
Review the current MCDA landscape, outline the best practices for conducting MCDA, and discuss the steps involved in conducting MCDA.
Biosimilars on the Red Carpet: The Pharmacoeconomics of Their American Debut

This symposium will feature a multifaceted discussion of biosimilar drugs as they enter the U.S. marketplace in 2015. Speakers will address the U.S. regulatory environment, clinical and economic drivers of biosimilar uptake, pricing strategies, and other influential factors in payer decision making. (Sponsored by GalbraithWight)

6:30PM-7:30PM EDUCATIONAL SYMPOSIUM


This symposium will discuss the relative affordability of new therapies for advanced cancers, current pricing models and their drawbacks, methods for innovation in pricing from new medicines in advanced cancers, and practical application of innovative pricing models. (Sponsored by ProCE)

6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION

8:30PM-9:30PM ISPOR STUDENT & FACULTY ADVISOR RECEPTION

MONDAY, MAY 18

7:15AM-8:15AM EDUCATIONAL SYMPOSIUM

Does Real World Evidence, in the Guise of Patient Registries, Add Any Value to the Decision-Making Process?

Real world evidence, such as large scale patient registries, have often been proposed as potential sources of clinical, economic, patient reported, and safety outcomes evidence that can aid decision making in health care. The impact on payer reimbursement decisions will be discussed. (Sponsored by ICON)

8:30AM-2:15PM POSTERS - I

8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION

Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does It Matter?

Nearly a decade ago, leaders envisioned a pathway to a learning health care system, where research is closely integrated and rapidly translated into practice by making use of electronic data that can track patients across health care providers and time. Since then, there has been substantial public and private investment to make this vision a reality. This session critically examines how far we have come and what the implications are for comparative effectiveness researchers, payers, patients, and the life sciences industry.

Moderator: Penny Mohr, MA, Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Speakers: Sarah Greene, MPH, Associate Director, CER Methods and Infrastructure, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Sachin H. Jain, MD, MBA, Chief Medical Officer, CareMore/Anthem and Lecturer in Health Care Policy, Harvard Medical School, Cerritos, CA, USA; Lewis G. Sandy, MD, FACP, Senior Vice President, Clinical Advancement, UnitedHealth Group, Minneapolis, MN, USA

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS - I

11:00AM-12:00PM ISSUE PANELS - I

IP1: Should the Name of the Game be More “Skin in the Game”? The Scope and Consequences of Rx Cost-Shifting from Payers to Patients (Invited Issue Panel)

Moderator: Gerry Oster, PhD, Policy Analysis, Inc. and MINERVA Health Economics Network, Brookline, MA, USA
Panelists: Elizabeth Hargrave, MPA, University of Chicago, Chicago, IL, USA; Elise Gould, PhD, Economic Policy Institute, Washington, DC, USA; A. Mark Fendrick, MD, University of Michigan, Ann Arbor, MI, USA

IP2: Can We Afford Medical Breakthroughs for Large Prevalence Diseases? Lessons from Hepatitis C

Moderator: Dana P. Goldman, PhD, University of Southern California, Los Angeles, CA, USA
Panelists: Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Tomas J. Philipson, PhD, University of Chicago, Chicago, IL, USA; Adrian Towe, MA, MPhil, Office of Health Economics (OHE), London, UK
IP3: Are We Comfortable Applying Existing Quality-Driven Adherence Measurement Methodologies to Specialty Pharmaceutical Products and What Are the Risks, Especially If Using Administrative Claims Databases?

Moderator: Craig Schilling, Pharm.D, Optum, Eden Prairie, MN, USA
Panelists: Richard Faris, PhD, MSc, RPh, UCB, Inc., Smyrna, GA, USA; Michael Ingham, MSc, Janssen Scientific Affairs, LLC, Horsham, PA, USA; Stephen M Lund, RPh, Senderra Rx Specialty Pharmacy, Richardson, TX, USA
IP4: What Is the Value of Big Data in Comparative Effectiveness Research and Clinical Decision Making?

Moderator: William H. Crown, PhD, Optum Labs, Cambridge, MA, USA
Panelists: Miguel Hernan, MD, DrPH, Harvard T. Chan School of Public Health, Boston, MA, USA; Sarah Greene, MPH, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Milton C Weinstein, PhD, Harvard T. Chan School of Public Health, Boston, MA, USA
IP5: PROs and Beyond: Are They Fit for Purpose to Improve Health Care Policy and Practice?

Moderator: Corinna Sorenson, MPH, MHSA, PhD, Avalere Health, Washington, DC, USA
Panelists: Kristi Mitchell, MPH, Avalere Health, Washington, DC, USA; Mark McClellan, MD, PhD, Brookings Institution, Washington, DC, USA; Sachin Kamal-Bahl, PhD, Pfizer, Philadelphia, PA, USA

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS - 1

12:15PM-1:15PM EDUCATIONAL SYMPOSIUM

EQ-5D-5L: Development of the First National Tariffs

This symposium will discuss developments in EQ-5D-5L value sets programs and their use in supporting outcome-based studies. A value set approach and new value set for England will also be presented. A user perspective will be presented, together with an outline for future research. (Sponsored by EuroQol Research Foundation)

12:15PM-1:15PM ISPOR STUDENT RESEARCH SHOWCASE

1:15PM-2:15PM POSTER AUTHOR DISCUSSION HOUR - 1

2:15PM-3:15PM RESEARCH PODIUMS - 1

CARDIOVASCULAR DISEASE RESEARCH STUDIES

CV1: Lifetime Health Care Costs of Obesity-Related Comorbidities in the United States, 2007-2010

CV2: The Association between Adherence to Cardiovascular Medications and Health Care Utilization

CV3: Prevalence and Direct Medical Costs Associated With Angina and Chest Pain Following Percutaneous Coronary Intervention in the United States

CV4: Outcomes and Health Resource Utilization among Patients with Heart Failure with Reduced Ejection Fraction (HFREF) at an Academic Medical Center (AMC) in the United States

RESEARCH ON DATABASE METHODS STUDIES

DB1: Critical Problems of Coding Data in Health Care: Obesity, Smoking, and Alcohol Use by Method of Measurement

DB2: A New Method for Counting Hemophilia-Related Bleeding Events in Claims Data

DB3: The Implications of Using a 30-, 60-, Or 90-Day Gap in Treatment to Specify Lines of Care in Gastric Cancer Treatment

DB4: Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database

HEALTH CARE MANAGEMENT STUDIES

HM1: Utilization of Antidiabetics after FDA Safety Announcements

HM2: Differences in Mastectomy Rates Based on Hormone Receptor Status in Early Stage Tumors: A SEER Database Analysis
TUESDAY, MAY 19

7:15AM-8:15AM EDUCATIONAL SYMPOSIA

Leveraging Electronic Medical Records and Online Data for HEOR Research: Opportunities and Cautions

This session will discuss recent advances in Electronic Medical Records (EMR) systems, analytical techniques, and software to mine new data sources for health economics and outcomes research (HEOR). Examples where nontraditional data sources have been utilized will be studied and potential issues of over-interpretation and over-reliance of data with suboptimal quality will be presented. (Sponsored by Analysis Group)

8:30AM-2:15PM POSTERS - III

8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?

In recent years, both oncology and cardiology professional organizations have embraced the explicit consideration of cost-effectiveness and the value of treatments in developing and updating clinical practice guidelines and clinical pathways. This is a new development in the U.S. health care system, and one which is complicated by the pluralistic nature of the system. The impact that it could ultimately have on medical practice is not clear neither in terms of access to care and providers nor in terms of incentives for innovation. This session will explore the implications of this change for the range of stakeholders involved, including U.S. private insurers, clinicians, patients, and federal government programs.

Moderator: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

Speakers: Mark A. Hlatky, MD, Professor of Health Research and Policy & Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA; Peter P. Yu, MD, FACP, FASCO, Director of Cancer Research, Palo Alto Medical Foundation, Sunnyvale, CA and President, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA; Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Harlington, York, UK

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS - III

11:00AM-12:00PM ISSUE PANELS - III

IP6: How Should the FDA Regulate the Communication of Health Economic Data by Pharmaceutical Companies to Payers?

Moderator: Peter J. Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Panelists: Laurie Burke, MPH, RPh, LORA Group, Royal Oak, MD, USA; Joseph Jackson, PhD, Health Outcomes Insights LLC, Lavalalette, NJ, USA; Alan Bennett, JD, Mothers & Gray, Washington, DC, USA

IP7: New Models of Cancer Reimbursement: Are There Consequences for Spending and Patient Health?

Moderator: Amitabh Chandra, PhD, Harvard University, Cambridge, MA, USA

Panelists: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA; Jennifer Malin, MD, PhD, Anthem, Woodland Hills, CA, USA

IP8: Challenges and Opportunities for Pragmatic Clinical Trials – Should Europe and the United States Approach Them Differently?

Moderator: Rafael Alfonso-Cristancho, MD, PhD, MSc, GlaxoSmithKline (GSK), King of Prussia, PA, USA

Panelists: Bryan R Luce, PhD, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Tjeerd Van Staa, MD, PhD, MSc, University of Manchester, Manchester, UK

IP9: Continuous Patient Engagement: How Do We Partner with Patients Throughout the Research Life Cycle?

Moderator: C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA

Panelists: Emily Chiauzzi, PhD, PatientsLikeMe, Cambridge, MA, USA; Daniel Frye, JD, NJ Commission for the Blind and Visually Impaired, Newark, NJ, USA; Marvin Mack, Center for Mind & Esteem Development, Baltimore, MD, USA

IP10: Early Access to Medicines: What Is in It for Payers?

Moderator: Adam Heathfield, PhD, Pfizer, Surrey, UK

Panelists: Adrian Towsie, MA, MPhil, Office of Health Economics, London, UK; Mark Trusheim, MS, Massachusetts Institute of Technology, Cambridge, MA, USA; Dan Ollendorf, PhD, Institute for Clinical and Economic Review, Boston, MA, USA

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – III

12:15PM-1:15PM EDUCATIONAL SYMPOSIA

Dissemination of Health Economic Evidence to US Payers under FDAMA Section 114 – Lessons from the Past and New Guidance Expected

Trends in sharing health economic information under Section 114 will be discussed. Perspectives of how pharmaceutical companies are handling the dissemination of health economic information as well as receipt of information by managed care will be shared and discussed in detail. (Sponsored by Xcenda)

1:15PM-2:15PM ISPOR ANNUAL BUSINESS MEETING

2:15PM-3:15PM ISSUE PANELS - III

IP11: The $2.6 Billion Question: Why Are Drug Development Costs Rising and Can We Afford It? (Invited Issue Panel)

Moderator: Lou Garrison, PhD, University of Washington, Seattle, WA, USA

Panelists: Joseph A. DiMasi, PhD, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA; Patricia M. Danzon, PhD, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA; Adrian Towsie, MA, MPhil, Office of Health Economics, London, UK

IP12: Patient-Focused Drug Development: Are Policy Makers Listening?

Moderator: John F Bridges, PhD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Panelists: Mark Walderhaug, AB, PhD, U.S. Food & Drug Administration, Silver Spring, MD, USA; Holly Peay, PhD, Parent Project Muscular Dystrophy, Hackensack, NJ, USA; Frank W Rockhold, PhD, GlaxoSmithKline, Cary, NC, USA
MEETING PROGRAM CONTINUED

5:00PM-6:00PM  WORKSHOPS - III

W15: The ISPOR MCDA Task Force: How Best to Use It in Health Care Decision Making
Discussion Leaders: Maarten J. Uzerman, PhD, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, the Netherlands; Nancy Devlin, PhD, Office of Health Economics, London, UK; Praveen Thokala, PhD, University of Sheffield, Sheffield, UK; Kevin Marsh, PhD, Evidera, London, UK
W16: Maximizing the Utility of Real World Evidence: Integration of Structured EMR Data, Unstructured EMR Data, and Billing Data for Economics and Outcomes Research in Oncology
Discussion Leaders: Mark S Walker, PhD, Vector Oncology, Memphis, TN, USA; Kathy L. Schulman, MS, Outcomes Research Solutions, Inc., Bolton, MA, USA; Arlene Ravelo, MPH, Genentech, Inc., South San Francisco, TN, USA; Kim Saverno, PhD, RPh, Vector Oncology, Memphis, TN, USA
W17: Informatics and Interoperability: Speaking the Same Language
Discussion Leaders: Scott D Nelson, PharmD, MS, Department of Veterans Affairs, Salt Lake City, UT, USA; Olivier Bodenreider, MD, PhD, U.S. National Library of Medicine, Bethesda, MD, USA; Richard Boyce, PhD, University of Pittsburgh, Pittsburgh, PA, USA; Daniel C. Malone, PhD, RPh, MS, University of Arizona, Tucson, AZ, USA
W18: Surviving the Submission: Best Practices in Overall Survival Extrapolation in Oncology
Discussion Leaders: Sanatan Shreay, PhD, Gilead Sciences, Foster City, CA, USA; Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Rachel Beckerman, PhD, CBPartners, New York, NY, USA; Petros Pechlivanoglou, PhD, Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada

W9: Methodological Choices for Analyzing Cluster-Correlated Data in Large Patient Databases
Discussion Leaders: Steve Sherman, MPH, Creative-Ceutical, Chicago, IL, USA; Katia Thokagevitsk, PhD, Creative-Ceutical, Chicago, IL, USA; Firas Dabbous, MS, University of Illinois at Chicago, Chicago, IL, USA; Samuel Aballéa, MSc, Bristol-Myers Squibb, New York, NY, USA

W10: Rare Diseases in the Era of Big Data: Selection Bias in Small Samples
Discussion Leaders: Nicole M. Engel-Nitz, PhD, Optum, Eden Prairie, MN, USA; Zhimei Liu, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Cori Blauer-Peterson, MPH, Optum, Eden Prairie, MN, USA; Jonathan C. Johnson, MS, Optum, Eden Prairie, MN, USA
W11: Can We Make Comparative Effectiveness Useful for Clinicians and Patients or Is It Just for Health Technology Assessments?
Discussion Leaders: Edward J Mills, PhD, MSc, Stanford University, Stanford, CA, USA; Christopher O’Regan, MSc, Merck Sharp & Dohme Limited, Hertfordshire, UK; Sonal Singh, MD, MPH, Johns Hopkins University, Baltimore, MD, USA

W12: Issues to Consider When Estimating Health Care Costs with Generalized Linear Models (GLMs): To Gamma/Log or Not to Gamma/Log?
That is the New Question
Discussion Leaders: Jaipa A. Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA; Henry Glick, PhD, University of Pennsylvania, Philadelphia, PA, USA; Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
W13: Patient- And Observer-Reported Outcomes (PROs & ObsROs) Measurement in Rare Disease Clinical Trials - Emerging Good Practices
Discussion Leaders: Katy Benjamín, PhD, MS, ICON, Bethesda, MD, USA; Eleanor Perfetto, PhD, MS, University of Maryland, Baltimore, MD, USA; Laurie Burke, MPH, RPh, LORA Group, Royal Oak, MD, USA; Donald L. Patrick, PhD, MSPH, University of Washington, Seattle, WA, USA
W14: Charting a Path for the Elicitation of Preferences: Perspectives on the Effective Use of Preference-Elicitation Methods
Discussion Leaders: Josephine A. Mauskopf, PhD, RTh Health Solutions, Research Triangle Park, NC, USA; Maarten J. Uzerman, PhD, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, the Netherlands; Juan Marcos Gonzalez, PhD, RTh Health Solutions, Research Triangle Park, NC, USA
MEETInG PROGRAM COnTInUED

11:00AM-11:30AM  
AcademyHealth, Cambridge, USA, MA  
Panelists:  
- Anupam B. Jena, MD, PhD, Harvard Medical School, Boston, MA, USA  
- Karen Schoelles, MD, SM, University of Washington, Seattle, WA, USA  
- Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA  
IP17: Value-Based Formulary Design (VBFD): Is Premera a Voice Crying in the Wilderness?  
Moderator: Kathleen E. Hughes, MBA, Avalere Health LLC, Washington, DC, USA  
Panelists:  
- Dan Danielson, MS, RPh, Premera Blue Cross, Mountlake Terrace, WA, USA  
- Edmund J. Pazella, MD, MPH, Aetna, Inc., Hartford, CT, USA  
- John Graham, PharmD, GlaxoSmithKline, King of Prussia, PA, USA  
IP18: Competitive Bidding for Therapeutically-Equivalent Branded Pharmaceuticals: Promise or Threat?  
Moderator: Josephine A. Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA  
Panelists:  
- David W. Miller, PhD, Biogen Idec, Maidenhead, UK  
- Susan Hogue, PharmD, MPH, RTI International, Research Triangle Park, NC, USA  
IP19: Ready for Risk Sharing? Challenges and Implications for Manufacturers  
Moderator: Kim White, MBA, Numerof & Associates, St. Louis, MO, USA  
Panelists:  
- Kevin Conlin, MA, Horizon Blue Cross Blue Shield, Newark, NJ, USA  
- Bryan Gilpin, SM, Boston Scientific Corporation, Marlborough, MA, USA  
- Sherry Thornton, Medtronic, Inc., Memphis, TN, USA  
IP20: Application of PROMIS Tools in Pharmaceutical and Device Industry Studies: Are We Moving the Wheel Forward?  
Moderator: Stacie Hugdins, MA (ABD), Clinical Outcomes Solutions, Tucson, AZ, USA  
Panelists:  
- David Cella, PhD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA  
- Ashley Slagle, PhD, U.S. Food and Drug Administration, Silver Spring, MD, USA  
- Rajiv Mallick, BTG International Inc., West Conshohocken, PA, USA  
2:45PM-3:00PM  
BREAK & EXHIBITS - V  
3:00PM-4:00PM  
WORKSHOPS - V  
W27: Back to the Future: Learning the Lessons in Valuing EQ-5D-3L Health States  
Discussion Leaders: Paul Kind, University of Leeds, Leeds, UK; Roisin Adams, PhD, National Centre for Pharmacoeconomics, Dublin, Ireland; Mónica Viegas, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil  
Discussion Leaders: Elise Berliner, PhD, Agency for Healthcare Research and Quality, Rockville, MD, USA; Karen Schoelles, MD, SM, ECRI Institute, Plymouth Meeting, PA, USA; Marcus Lynch, PhD, ECRI Institute, Plymouth Meeting, PA, USA; Jalpa A. Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA  
W29: Strategies for Assessing the Patient-Level Economic Impact of Cancer Diagnosis  
Discussion Leaders: Veena Shankaran, MD, MS, University of Washington, Seattle, WA, USA; Amy Davidoff, PhD, MS, Yale School of Public Health, New Haven, CT, USA; Representative from Interagency Consortium to Promote Health Economics Research on Cancer (HEROiC)  
W30: Warranting Budget Predictability through Managed Entry Agreements and Insurance-Based Mechanisms  
Discussion Leaders: Olivier Ethgen, MSc, PhD, University of Liege, Liege, Belgium; Augustin Terlinden, MSc, BLUE ANTIDOTE, Tervuren, Belgium  
W31: Developments and Communication Since the Issuance of FDA’s Guidance to Industry on Patient-Reported Outcomes: Then and Now  
Discussion Leaders: Brooke Witherspoon, BA, Endpoint Outcomes, Boston, MA, USA; Somali Misra Burgess, PhD, Strategic Outcomes Services, Mission Viejo, CA, USA; Kristina Fitzgerald, MPH, Genentech Inc., South San Francisco, CA, USA; Paivi Miskala, MSPH, PhD, ProCon Global, LLC, Rockville, MA, USA

Complete meeting information available at: www.ispor.org